Document is current

Any future updates will be listed below

Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer—biweekly versus standard triweekly XELOX (The ORION Study)

Crossref DOI link: https://doi.org/10.1007/s10147-015-0911-7

Published Online: 2015-10-16

Published Print: 2016-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark